Details for New Drug Application (NDA): 207777
✉ Email this page to a colleague
NDA 207777 describes APREPITANT, which is a drug marketed by Glenmark Speclt, Sandoz, and Torrent, and is included in three NDAs. It is available from three suppliers. Additional details are available on the APREPITANT profile page.
The generic ingredient in APREPITANT is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
The generic ingredient in APREPITANT is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
Summary for 207777
| Tradename: | APREPITANT |
| Applicant: | Glenmark Speclt |
| Ingredient: | aprepitant |
| Patents: | 0 |
Suppliers and Packaging for NDA: 207777
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| APREPITANT | aprepitant | CAPSULE;ORAL | 207777 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-112 | 68462-112-33 | 1 KIT in 1 DOSE PACK (68462-112-33) * 2 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK |
| APREPITANT | aprepitant | CAPSULE;ORAL | 207777 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-583 | 68462-583-11 | 1 BLISTER PACK in 1 CARTON (68462-583-11) / 10 CAPSULE in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 40MG | ||||
| Approval Date: | Oct 12, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 80MG | ||||
| Approval Date: | Oct 12, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 125MG | ||||
| Approval Date: | Oct 12, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
